Mel Schatz

InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that. InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation. InterVene's offices are now located in South San Francisco near SFO airport.

Sword Bio is a bioanalytical CRO committed to delivering projects with the best-in-class quality, science, service, and speed. We are a team of experts in the bioanalytical CRO field, bringing over 30 years of experience to your project. We specialize in developing, qualifying and validating PK, Biomarkers and immunogenicity assays. At Sword Bio, we have the flexibility to respond to your evolving needs, from assay development to clinical testing in an Non-GLP or GLP environment. We will work with you to maximize your resources and begin your projects immediately, priding ourselves on timely results and open communication. Sword Bio offers a rapid, customized, collaborative and an accessible new way of working with a CRO. Sword’s mission is the same as yours: to quickly and reliably bring essential drugs to those who need them.

InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that. InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation. InterVene's offices are now located in South San Francisco near SFO airport.

Sword Bio is a bioanalytical CRO committed to delivering projects with the best-in-class quality, science, service, and speed. We are a team of experts in the bioanalytical CRO field, bringing over 30 years of experience to your project. We specialize in developing, qualifying and validating PK, Biomarkers and immunogenicity assays. At Sword Bio, we have the flexibility to respond to your evolving needs, from assay development to clinical testing in an Non-GLP or GLP environment. We will work with you to maximize your resources and begin your projects immediately, priding ourselves on timely results and open communication. Sword Bio offers a rapid, customized, collaborative and an accessible new way of working with a CRO. Sword’s mission is the same as yours: to quickly and reliably bring essential drugs to those who need them.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.html Privacy Policy: https://abbo.tt/privacy